(Total Views: 219)
Posted On: 10/26/2017 10:52:40 AM
Post# of 72446
From today's PR :
" In addition, the Company plans to apply for FDA Breakthrough Therapy Designation should top-line end of study results reflect similar efficacy (and safety) to that observed at interim, in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo."
In that statement , " should top-line end of study results reflect similar efficacy (and safety) to that observed at interim"
So,even though IPIX didn't release interim data,that doesn't mean they didn't see it.And what did they see???
As said in the above statement :
" in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo."
Mgt.is sharing that they already know where this is headed and are sharing their confidence with us as well as adding a little more pressure to the CDA holders.
Kelt
" In addition, the Company plans to apply for FDA Breakthrough Therapy Designation should top-line end of study results reflect similar efficacy (and safety) to that observed at interim, in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo."
In that statement , " should top-line end of study results reflect similar efficacy (and safety) to that observed at interim"
So,even though IPIX didn't release interim data,that doesn't mean they didn't see it.And what did they see???
As said in the above statement :
" in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo."
Mgt.is sharing that they already know where this is headed and are sharing their confidence with us as well as adding a little more pressure to the CDA holders.
Kelt
(6)
(0)
